Archived research. Equity forecasting is part of the Runchey Research archive (methodology era 1) and is no longer actively updated. Everything remains published at its original URL. Browse the archive
Back to Forecasting
INSM Forecast Markets
Insmed Incorporated
7
Active Markets
53%
Avg Probability
All Markets
7 markets
Will the ENCORE Phase III trial for ARIKAYCE meet its primary endpoint?
50%
Likely No
97% agreement
Jun 30, 2026
IG: 1.00
Will BRINSUPRI net revenue exceed $200M in Q1 2026?
57%
Likely Yes
97% agreement
May 15, 2026
IG: 0.80
Will BRINSUPRI generate $1B+ in net revenue for FY2026?
43%
Likely No
97% agreement
Feb 28, 2027
IG: 0.80
Will BRINSUPRI repeat prescriber rate exceed 60% by mid-2026?
50%
Likely No
97% agreement
Aug 15, 2026
IG: 0.64
Will BRINSUPRI's gross-to-net adjustment remain below 35% through FY2026?
67%
Likely Yes
97% agreement
Feb 28, 2027
IG: 0.48
Will Insmed's quarterly operating cash burn stay below $300M in Q1 and Q2 2026?
52%
Likely Yes
97% agreement
Aug 15, 2026
IG: 0.48
Will Insmed begin PALM-PAH Phase III enrollment by end of H1 2026?
55%
Likely Yes
97% agreement
Jul 15, 2026
IG: 0.48
Resolution Timeline
Aug 15, 2026
Will Insmed's quarterly operating cash burn stay below $300M in Q1 and Q2 2026?Prediction: 52%
Feb 28, 2027
Will BRINSUPRI's gross-to-net adjustment remain below 35% through FY2026?Prediction: 67%